Nichols & Pratt Advisers LLP MA continued to hold its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,925 shares of the medical research company’s stock at the end of the 2nd quarter. Nichols & Pratt Advisers LLP MA’s holdings in Amgen were worth $676,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. TrimTabs Asset Management LLC grew its holdings in Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after purchasing an additional 288 shares during the period. American Beacon Advisors Inc. bought a new stake in Amgen during the first quarter valued at about $106,000. Nelson Roberts Investment Advisors LLC bought a new stake in Amgen during the first quarter valued at about $121,000. Grove Bank & Trust grew its holdings in Amgen by 87.4% during the second quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock valued at $126,000 after purchasing an additional 341 shares during the period. Finally, Enterprise Financial Services Corp grew its holdings in Amgen by 18.0% during the second quarter. Enterprise Financial Services Corp now owns 748 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 114 shares during the period. 78.20% of the stock is owned by institutional investors.
Several equities analysts have recently commented on the company. Royal Bank Of Canada assumed coverage on Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective on the stock. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. BMO Capital Markets downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 target price on the stock. in a research report on Friday, July 21st. They noted that the move was a valuation call. Credit Suisse Group reiterated a “neutral” rating and issued a $186.00 target price (up from $177.00) on shares of Amgen in a research report on Friday, September 29th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $209.00 target price on shares of Amgen in a research report on Saturday, July 22nd. Thirteen research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $190.03.
Amgen Inc. (NASDAQ AMGN) opened at $170.13 on Wednesday. Amgen Inc. has a 52 week low of $138.83 and a 52 week high of $191.10. The stock has a market capitalization of $124,493.66, a P/E ratio of 13.63, a P/E/G ratio of 2.48 and a beta of 1.37. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. Amgen’s revenue was down .7% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.02 earnings per share. analysts expect that Amgen Inc. will post 12.66 EPS for the current year.
Amgen announced that its board has authorized a share repurchase program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be issued a dividend of $1.15 per share. The ex-dividend date is Thursday, November 16th. This represents a $4.60 dividend on an annualized basis and a yield of 2.70%. Amgen’s dividend payout ratio is currently 41.63%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $171.58, for a total transaction of $261,659.50. Following the completion of the sale, the executive vice president now owns 57,631 shares in the company, valued at $9,888,326.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,050 shares of company stock valued at $1,239,673. 0.19% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://transcriptdaily.com/2017/11/15/nichols-pratt-advisers-llp-ma-has-676000-holdings-in-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.